// App-Quantinova.ai

607 : Role of tumor infiltrating lymphocytes (TILs) in HER2+ metastatic breast cancers (MBC) treated with trastuzumab emtansine (T-DM1) or lapatinib plus capecitabine (L+C) (EMILIA Trial).

Researchers

Presenter

  • Sunil S. Badve

Principal Investigators

  • Yesim Gokmen-Polar

  • Silke Hoersch

  • Jin Xu

  • Josef Ruschoff

  • Sanne de Haas

  • Sunil Verma

Medical Centers

  • Indiana University, Indianapolis, IN

  • Indiana University School of Medicine, Indianapolis, IN

  • Dr. Manfred Kohler GmbH/Roche, Freiburg, Germany

  • Genentech, Inc., South San Francisico, CA

  • Institut fur Pathologie Nordhessen and Targos Molecular Pathology GmbH, Kassel, Germany

  • F. Hoffmann-La Roche Ltd., Basel, Switzerland

  • Cumming School of Medicine, University of Calgary, Calgary, AB, Canada

Locations

  • United States

  • Germany

  • Switzerland

  • Canada

Companies

  • Feng Chi Biotech Cor

  • Genentech, Inc.

  • F. Hoffmann-La Roche

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Breast cancer

Biomarkers

  • erb-b2 receptor tyrosine kinase 2

  • tumor-infiltrating lymphocytes

Drug/Treatment

  • Trastuzumab emtansine

  • Capecitabine

  • Trastuzumab

  • Lapatinib

Outcome

  • N/A

Study Design

  • Double Blind/Blinded

Phase

  • III

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved